Matt S.
09-30-07, 04:20 PM
I read in Time magazine recently that MDMA was undergoing clinical trials for the treatment of Post Traumatic Stress Disorder, MDMA is Methylenedioxymethamphetamine or ecstasy
This is more what I think it meant:
Some scientists have suggested that MDMA may facilitate self-examination with reduced fear, which may prove useful in some therapeutic settings. In 1980, psychiatrist George Greer synthesized MDMA in the lab of Alexander Shulgin, then administered it to about 80 of his clients over the next five years, until MDMA was scheduled in 1985. In a published summary of the effects,<SUP class=reference id=_ref-8>[12] (http://en.wikipedia.org/wiki/Methylenedioxymethamphetamine#_note-8)</SUP> subjects reported improvements in various, mild psychiatric disorders and other personal benefits, especially improved intimate communication with their significant others. In a subsequent publication on the treatment method, one patient with severe pain from terminal cancer reported definitive and lasting pain relief and improved quality of life.<SUP class=reference id=_ref-9>[13] (http://en.wikipedia.org/wiki/Methylenedioxymethamphetamine#_note-9)</SUP>
In 2001, the FDA granted permission for experimental administration of MDMA to patients suffering from post-traumatic stress disorder (http://en.wikipedia.org/wiki/Post-traumatic_stress_disorder). This research is being sponsored by the Multidisciplinary Association for Psychedelic Studies (http://en.wikipedia.org/wiki/Multidisciplinary_Association_for_Psychedelic_Stud ies) (MAPS).<SUP class=reference id=_ref-10>[14] (http://en.wikipedia.org/wiki/Methylenedioxymethamphetamine#_note-10)</SUP> A parallel similar study is currently underway in Switzerland which should finish in 2008.<SUP class=reference id=_ref-11>[15] (http://en.wikipedia.org/wiki/Methylenedioxymethamphetamine#_note-11)</SUP> This research in patients builds on studies in which MDMA was given to healthy volunteers. The first of these healthy volunteer studies was conducted by Dr. Charles Grob, with other studies done by Dr. Franz Vollenweider in Switzerland, Drs. John Mendelson and Reese Jones at the University of California San Francisco, and Drs. Magi Faree and Rafael de la Torre in Spain.
It has been proposed that MDMA should be considered the prototypical member of a novel category of drug, called "empathogen" and/or "entactogen."<SUP class=reference id=_ref-12>[16] (http://en.wikipedia.org/wiki/Methylenedioxymethamphetamine#_note-12)</SUP><SUP class=reference id=_ref-13>[17] (http://en.wikipedia.org/wiki/Methylenedioxymethamphetamine#_note-13)</SUP>
This is more what I think it meant:
Some scientists have suggested that MDMA may facilitate self-examination with reduced fear, which may prove useful in some therapeutic settings. In 1980, psychiatrist George Greer synthesized MDMA in the lab of Alexander Shulgin, then administered it to about 80 of his clients over the next five years, until MDMA was scheduled in 1985. In a published summary of the effects,<SUP class=reference id=_ref-8>[12] (http://en.wikipedia.org/wiki/Methylenedioxymethamphetamine#_note-8)</SUP> subjects reported improvements in various, mild psychiatric disorders and other personal benefits, especially improved intimate communication with their significant others. In a subsequent publication on the treatment method, one patient with severe pain from terminal cancer reported definitive and lasting pain relief and improved quality of life.<SUP class=reference id=_ref-9>[13] (http://en.wikipedia.org/wiki/Methylenedioxymethamphetamine#_note-9)</SUP>
In 2001, the FDA granted permission for experimental administration of MDMA to patients suffering from post-traumatic stress disorder (http://en.wikipedia.org/wiki/Post-traumatic_stress_disorder). This research is being sponsored by the Multidisciplinary Association for Psychedelic Studies (http://en.wikipedia.org/wiki/Multidisciplinary_Association_for_Psychedelic_Stud ies) (MAPS).<SUP class=reference id=_ref-10>[14] (http://en.wikipedia.org/wiki/Methylenedioxymethamphetamine#_note-10)</SUP> A parallel similar study is currently underway in Switzerland which should finish in 2008.<SUP class=reference id=_ref-11>[15] (http://en.wikipedia.org/wiki/Methylenedioxymethamphetamine#_note-11)</SUP> This research in patients builds on studies in which MDMA was given to healthy volunteers. The first of these healthy volunteer studies was conducted by Dr. Charles Grob, with other studies done by Dr. Franz Vollenweider in Switzerland, Drs. John Mendelson and Reese Jones at the University of California San Francisco, and Drs. Magi Faree and Rafael de la Torre in Spain.
It has been proposed that MDMA should be considered the prototypical member of a novel category of drug, called "empathogen" and/or "entactogen."<SUP class=reference id=_ref-12>[16] (http://en.wikipedia.org/wiki/Methylenedioxymethamphetamine#_note-12)</SUP><SUP class=reference id=_ref-13>[17] (http://en.wikipedia.org/wiki/Methylenedioxymethamphetamine#_note-13)</SUP>